Joint Formulary & PAD

Co-proxamol (Dextropropoxyphene hydrochloride/paracetamol) - Pain

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

PAD Profile

ChemicalSubstance :
Co-proxamol (Dextropropoxyphene hydrochloride/paracetamol)
Indication :
Pain
Group Name :
Keywords :
coproxamol, low value medicines, drugs of low clinical value, LVM, drugs of limited clinical value, analgesia, analgesics, Items which should not be routinely prescribed in primary care
Brand Names Include :
Distalgesic, Cosalgesic, Dolgesic,
Important Information :

No longer licensed because of safety concerns, particularly toxicity in overdose.

Listed in 'Items which should not routinely be prescribed in primary care: policy guidance'. Click drug name for details. 

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
4

Committee Recommendations (1)

The Prescribing Clinical Network does not recommend the use of co-proxamol. Co-proxamol will be considered NON-FORMULARY on the traffic light system. Prescribers should: - NOT initiate co-proxamol for any new patient AND - Switch patients taking co-proxamol to an alternative pain medication, in line with NHS England guidance.